Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of CM310 Under Background Treatment in Patients With Seasonal Allergic Rhinitis Inadequately Controlled With Current Recommended Therapies
Conditions
Interventions
CM310
Placebo
Locations
1
China
Beijing Tong-Ren hospital
Beijing, China
Start Date
August 10, 2023
Primary Completion Date
December 4, 2023
Completion Date
December 4, 2023
Last Updated
November 8, 2024
NCT06732414
NCT05494346
NCT06061848
NCT06603935
NCT06151938
NCT05186025
Lead Sponsor
Keymed Biosciences Co.Ltd
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions